quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:06:39·45d
ANALYSTRating
Aktis Oncology Inc. logo

H.C. Wainwright initiated coverage on Aktis Oncology with a new price target

AKTS· Aktis Oncology Inc.
Health Care
Original source

Companies

  • AKTS
    Aktis Oncology Inc.
    Health Care

Recent analyst ratings

  • Mar 9UpdateH.C. Wainwright$30.00
  • Feb 3UpdateAnalyst$30.00
  • Feb 3UpdateBofA Securities$34.00
  • Feb 3UpdateLeerink Partners$31.00
  • Feb 3UpdateTD Cowen-
  • Jan 4UpdatePiper Sandler$1.00

Related

  • INSIDER7d
    SEC Form 4 filed by Gormley Glenn
  • INSIDER7d
    SEC Form 3 filed by new insider Gormley Glenn
  • SEC7d
    SEC Form 8-K filed by Aktis Oncology Inc.
  • PR7d
    Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
  • SEC24d
    SEC Form 10-K filed by Aktis Oncology Inc.
  • PR24d
    Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
  • PR58d
    Aktis Oncology to Present at Upcoming March Investor Conferences
  • PR58d
    Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022